Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bret Bielawski

Internal Medicine Rochester Hills, MI Doctor of Osteopathy

NPI 1437149671 CMS profile 336968

1701 South Blvd E, Ste 290, Rochester Hills, MI 48307

Open in the dashboard

General payments

$4,294

290 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bret Bielawski of Rochester Hills, MI is reported in the CMS Open Payments database as having received $4,294 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $96 4
2024 General $63 3
2023 General $1,243 70
2022 General $1,328 82
2021 General $165 11
2020 General $251 18
2019 General $1,148 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bret Bielawski
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bret Bielawski were reported at $96. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bret Bielawski Internal Medicine median Middle half National median
2019 $1,148 $159 $48–$570 $163
2020 $251 $119 $33–$402 $114
2021 $165 $135 $37–$521 $132
2022 $1,328 $141 $42–$496 $149
2023 $1,243 $149 $45–$519 $160
2024 $63 $154 $47–$537 $164
2025 $96 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $565 36 payments
  2. Lilly USA, LLC $420 34 payments
  3. Novo Nordisk Inc $409 31 payments
  4. Amgen Inc. $382 26 payments
  5. Janssen Pharmaceuticals, Inc $316 29 payments
  6. Abbott Laboratories $270 13 payments
  7. Merck Sharp & Dohme Corporation $231 22 payments
  8. Astellas Pharma US Inc $205 11 payments
  9. AbbVie, Inc. $191 10 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $186 12 payments
  11. Other $1,120 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,278 288 payments
  2. Education $16 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $316 29 payments
  2. PAXLOVID $301 15 payments
  3. Repatha $297 20 payments
  4. Ozempic $292 22 payments
  5. ELIQUIS $282 15 payments
  6. TRULICITY $265 22 payments
  7. Otezla $243 16 payments
  8. NURTEC ODT $239 12 payments
  9. JARDIANCE $226 21 payments
  10. MYRBETRIQ $205 11 payments
  11. Other $4,778 337 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

220

Median for Internal Medicine: 777

Drug cost

$2,887

Median for Internal Medicine: $73,373

Branded share of claims

5.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 57 $723
Tamsulosin Hcl Generic 11 $451
Rosuvastatin Calcium Generic 23 $407
Levothyroxine Sodium Generic 35 $400
Benazepril Hcl Generic 12 $275
Amlodipine Besylate-Benazepril Amlodipine Besylate/Benazepril Brand 13 $189
Omeprazole Generic 20 $155
Metformin Hcl Generic 16 $111
Amlodipine Besylate Generic 19 $102
Lisinopril Generic 14 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record